Can-Fite BioPharma

Can-Fite BioPharma (TASE:CFBI; NYSE MKT:CANF) is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities. The company has an advanced pipeline of proprietary compounds in phase 2 and 3 clinical development stage, which address autoimmune-inflammatory and cancer diseases.

Science
The company technology platform is based on the finding that the Gi protein coupled A3 adenosine receptor (A3AR) is highly expressed in inflammatory and cancer cells whereas low expression is found in normal body cells. High A3AR expression levels are also >> more...

Pipeline
Can-Fite has a number of drugs in various stages of research and development. The pipeline drugs are synthetic, highly specific agonists and an allosteric modulator, all target the A3 adenosine receptor. All drugs are orally bioavailable with an excellent >> more...

News
Sep 18, 2017
Can-Fite Files Patent Application to Treat Cytokine Release Syndrome, a Potentially Life-Threatening Complication of CAR-T Cell Therapy >> more...
Sep 1, 2017
Can-Fite Reports Second Quarter 2017 Financial Results & Provides Clinical Update >> more...

Homepage \| Contact us	only canfite.com